leadf
logo-loader
viewHumanigen, Inc.

Humanigen reveals first patient has been infused in ZUMA-19 study

The clincial trial is a multi-center open-label study involving 36 participants

Humanigen, Inc. -
The study is evaluating lenzilumab in combination with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma

Humanigen Inc (OTCQB:HGEN) revealed on Tuesday that the first patient had been infused in its Phase 1/2 clinical trial of a treatment for those with relapsed or refractory Large B-cell Lymphoma.

This so-called ZUMA-19 study is being conducted in collaboration with Kite, which is a Gilead Sciences (NASDAQ:GILD) company.

READ: Humanigen says lenzilumab drug delivers better recovery time for coronavirus-associated pneumonia in cross-trial analysis

"We are excited to see this clinical collaboration move forward as we seek to understand the potential benefit of lenzilumab being administered with CAR T therapy in patients with relapsed or refractory large B-cell lymphoma," Cameron Durrant, the chief executive officer of Humanigen said in a statement.

The trial is a multi-center open-label study involving 36 participants.

Humanigen, a clinical-stage pharma group, and Kite are evaluating Humanigen's therapy lenzilumab in combination with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma.

The group is also currently focused on preventing or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of the coronavirus (COVID-19 infection.

Contact the author at [email protected]

Quick facts: Humanigen, Inc.

Price: - -

OTCMKTS:HGEN
Market: OTCQB
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Humanigen chosen by National Institute of Health's upcoming coronavirus...

Humanigen Inc (OTCQB:HGEN) CEO Cameron Durrant tells Proactive that its lead drug candidate lenzilumab was selected for use in the National Institute of Health’s upcoming coronavirus trial. Durrant says lenz will be evaluated in the National Institute of Allergy and Infectious Diseases’...

on 07/31/2020

2 min read